
|**Balanced Wheel**|||**1193464**|||
|---|---|---|---|---|---|
|**Receipts andpayments accounts**|||||**CC16a**|
|**For the period**<br>**from**|Period start date<br>**01/04/2022**|**To**|Period end date<br>**31/03/2023**|||



## **Section A Receipts and payments** 

|**A1 Receipts**|**Unrestricted**<br>**funds**<br>**to the nearest**<br>**£**<br>**3,676**<br>**9,923**<br>**-**<br>**13,599**<br>**-**<br>**-**<br>**-**<br>**13,599**<br>**-**<br>**-**<br>**2**<br>**400**<br>**804**<br>**200**<br> **1,406**<br>**-**<br>**-**<br> **-**<br>**1,406**<br>**12,193**<br>**-**<br>**-                    236**<br>**11,957**|**Restricted**<br>**funds**<br>**to the nearest £**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-   # **<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**|**Endowment**<br>**funds**<br>**to the nearest £**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br> **-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**|**Total funds**<br>**to the nearest £**<br>**3,676**<br>**9,923**<br>**-**<br>**13,599**<br>**-**<br>**-**<br>**-**<br>**13,599**<br>**-**<br>**-**<br>**2**<br>**400**<br>**804**<br>**200**<br>**1,406**<br>**-**<br>**-**<br>**-**<br>**1,406**<br>**12,193**<br>**-**<br>**-                    236**<br>**11,957**|**Last year**<br>**to the nearest £**|
|---|---|---|---|---|---|
|Donation|**3,676**||||**1,773**|
|Grants|**9,923**||||**-**|
||**-**||||**-**|
|**_Sub total_**_(Gross income for_<br>_AR)_|**13,599**||||**1,773**|
|||||||
|**A2 Asset and investment sales,**<br>**(see table).**||||||
||**-**||||**-**|
||**-**||||**-**|
|**_Sub total_**|**-**||||**-**|
|**_Total receipts_**<br>**A3 Payments**||||||
||||||**1,773**|
|||||||
|Information Techno;ogy|**-**||||**1,476**|
|Zoom|**-**||||**144**|
|Bank Charges|**2**||||**-**|
|Professional Fees|**400**||||**-**|
|Website|**804**||||**189**|
|Independent Examination|**200**||||**200**|
|**_Sub total_ **|**1,406**||||**2,009**|
|||||||
|**A4 Asset and investment**<br>**purchases, (see table)**||||||
||**-**||||**-**|
||**-**||||**-**|
|**_Sub total_ **|**-**||||**-**|
|**_Total payments_**<br>**_Net of receipts/(payments)_**<br>**A5 Transfers between funds**<br>**A6 Cash funds last year end**<br>**_Cash funds this year end_**||||||
||||||**2,009**|
|||||||
||**12,193**|**-**|**-**|**12,193**|**-                   236**|
||**-**|**-**|**-**|**-**|**-**|
||**-                    236**|**-**|**-**|**-                    236**|**-**|
||**11,957**|**-**|**-**|**11,957**|**-                   236**|



CCXX R1 accounts (SS) 

01/03/2024 

1 



## **Section B Statement of assets and liabilities at the end of the period** 

|**Categories**<br>Signed by one or two trustees on<br>behalf of all the trustees<br>**B5 Liabilities**<br>**B3 Investment assets**<br>**B2 Other monetary assets**<br>**B4 Assets retained for the**<br>**charity’s own use**<br>**B1 Cash funds**|**Details**<br>**Details**<br>**_Total cash funds_**<br>(agree balances with receipts and payments<br>account(s))<br>Cash @31st March 2022<br>Cash @ 31 March 2023<br>**Details**<br>**Details**<br>**Details**<br>Signature<br>Michael Olajide|**Unrestricted**<br>**funds**<br>**Restricted**<br>**funds**<br>**to nearest £**<br>**to nearest £**<br>**-                        236**<br>**-**<br>**12,193**<br>**-**<br>**-**<br>**-**<br>**11,957**<br>**-**<br>OK<br>OK<br>**Unrestricted**<br>**funds**<br>**Restricted**<br>**funds**<br>**to nearest £**<br>**to nearest £**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**Fund to which**<br>**asset belongs**<br>**Cost (optional)**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**Fund to which**<br>**asset belongs**<br>**Cost (optional)**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**Fund to which**<br>**liability relates**<br>**Amount due**<br>**(optional)**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>Print Name<br>Michael Olajide|**Endowment**<br>**funds**<br>**to nearest £**|
|---|---|---|---|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||OK|
||||**Endowment**<br>**funds**<br>**to nearest £**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**Current value**<br>**(optional)**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**Current value**<br>**(optional)**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**When due**<br>**(optional)**|
|||||
|||||
|||||
|||||
|||||
|||||
||||Date of<br>approval|
||Michael Olajide|Michael Olajide|01/03/2024|
|||||



CCXX R2 accounts (SS) 

01/03/2024 

2 

